Hybrid Metabolic Activity-Related Prognostic Model and Its Effect on Tumor in Renal Cell Carcinoma

Figure 3

The validation of efficacy of the hybrid metabolic activity-related prognostic model. (a) ROC curves of 1, 3, and 5 years for the hybrid metabolic activity-related prognostic model in the training set. (b) Violin diagrams of the relationship between clinical characteristics (pathological grade, clinical stage, T stage, and tumor metastasis) and risk scores. (c) The nomogram based on clinicopathological parameters and the risk score shows that the risk score accurately predicts 1-, 3- and 5-year survival in patients with RCC (, , , ). (d) The calibration curve exhibits the consistency between the observed and predicted overall survival of patients in 1, 3, and 5 years. (e) Patients were grouped according to the expression of ALDH6A1, DLD, SLC25A4, and the corresponding K–M curves were drawn. (f) ROC curves of 1, 3, and 5 years for the hybrid metabolic activity-related prognostic model in the validation set. (g) The K–M curve of patients in high risk and low risk groups in the validation set.

(a)

(b)

(c)

(d)

(e)

(f)

(g)